Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma

BACKGROUND: The sensitivity of myelocytomatosis oncogene (MYC) amplified medulloblastoma to class I histone deacetylase (HDAC) inhibition has been shown previously; however, understanding the underlying molecular mechanism is crucial for selection of effective HDAC inhibitors for clinical use. The a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Ecker, Jonas, Thatikonda, Venu, Sigismondo, Gianluca, Selt, Florian, Valinciute, Gintvile, Oehme, Ina, Müller, Carina, Buhl, Juliane L, Ridinger, Johannes, Usta, Diren, Qin, Nan, van Tilburg, Cornelis M, Herold-Mende, Christel, Remke, Marc, Sahm, Felix, Westermann, Frank, Kool, Marcel, Wechsler-Reya, Robert J, Chavez, Lukas, Krijgsveld, Jeroen, Jäger, Natalie, Pfister, Stefan M, Witt, Olaf, Milde, Till
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Basic and Translational Investigations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906057/
https://ncbi.nlm.nih.gov/pubmed/32822486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa191
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge